atai Life Sciences to Participate in Upcoming Investor Conferences
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 9:55 A.M. EDT in New York. Additionally, atai will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference through a pre-recorded fireside chat on June 17 at 7:00 A.M. EDT in a virtual format. Both presentations will be available via webcast on the company's investor relations website, with replays available after the events.
atai Life Sciences (NASDAQ: ATAI), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per la salute mentale, ha annunciato la sua partecipazione a due conferenze per investitori previste per giugno 2025. La societ脿 prender脿 parte a una chiacchierata informale al Jefferies Global Healthcare Conference il 5 giugno alle 9:55 EDT a New York. Inoltre, atai presenter脿 al H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference tramite una chiacchierata preregistrata il 17 giugno alle 7:00 EDT in formato virtuale. Entrambe le presentazioni saranno disponibili in webcast sul sito web delle relazioni con gli investitori della societ脿, con repliche accessibili dopo gli eventi.
atai Life Sciences (NASDAQ: ATAI), una compa帽铆a biofarmac茅utica en etapa cl铆nica centrada en tratamientos de salud mental, ha anunciado su participaci贸n en dos pr贸ximas conferencias para inversores en junio de 2025. La empresa participar谩 en una charla informal en la Jefferies Global Healthcare Conference el 5 de junio a las 9:55 A.M. EDT en Nueva York. Adem谩s, atai presentar谩 en la H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference mediante una charla pregrabada el 17 de junio a las 7:00 A.M. EDT en formato virtual. Ambas presentaciones estar谩n disponibles v铆a webcast en el sitio web de relaciones con inversores de la compa帽铆a, con repeticiones accesibles despu茅s de los eventos.
atai Life Sciences (NASDAQ: ATAI)電� 鞝曥嫚 瓯搓皶 旃橂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 6鞗旍棎 鞐措Μ電� 霊� 臧滌潣 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃� 瓴冹瀯鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 6鞗� 5鞚� 鞓れ爠 9鞁� 55攵� EDT鞐� 雺挫殨鞐愳劀 鞐措Μ電� Jefferies Global Healthcare Conference鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 霕愴暅, atai電� 6鞗� 17鞚� 鞓れ爠 7鞁� EDT鞐� 臧�靸� 順曥嫕鞙茧 歆勴枆霅橂姅 H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference鞐愳劀 靷爠 雲鬼檾霅� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞚� 韱淀暣 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 霊� 氚滍憸 氇憪 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 頄夓偓 頉� 鞛嫓觳澊 臧�電ロ暕雼堧嫟.
atai Life Sciences (NASDAQ : ATAI), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les traitements de la sant茅 mentale, a annonc茅 sa participation 脿 deux conf茅rences pour investisseurs pr茅vues en juin 2025. L'entreprise participera 脿 une discussion informelle lors de la Jefferies Global Healthcare Conference le 5 juin 脿 9h55 EDT 脿 New York. De plus, atai pr茅sentera lors de la H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference 脿 travers une discussion informelle pr茅enregistr茅e le 17 juin 脿 7h00 EDT en format virtuel. Les deux pr茅sentations seront disponibles en webdiffusion sur le site des relations investisseurs de la soci茅t茅, avec des rediffusions accessibles apr猫s les 茅v茅nements.
atai Life Sciences (NASDAQ: ATAI), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Behandlungen im Bereich der psychischen Gesundheit, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Juni 2025 angek眉ndigt. Das Unternehmen wird am 5. Juni um 9:55 Uhr EDT in New York an einem Fireside-Chat auf der Jefferies Global Healthcare Conference teilnehmen. Zus盲tzlich wird atai am 17. Juni um 7:00 Uhr EDT im Rahmen der H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference eine vorab aufgezeichnete Fireside-Chat-Pr盲sentation in virtueller Form halten. Beide Pr盲sentationen werden per Webcast auf der Investor-Relations-Website des Unternehmens verf眉gbar sein, mit Wiedergabem枚glichkeiten nach den Veranstaltungen.
- None.
- None.
NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- 聽 (NASDAQ: ATAI) (鈥渁tai鈥� or 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company鈥檚 management team聽is scheduled to聽participate in the following investor conferences in June:
Jefferies Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Thursday, June 5 at 9:55 A.M. EDT
- Location: New York
- Webcast link:
H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
- Format: Pre-recorded Fireside Chat
- Date and Time: Tuesday, June 17 at 7:00 A.M. EDT
- Location: Virtual
- Webcast link:
The webcasts of the fireside chats will also be available on the Investors section of the atai website under . A replay will be available following the live event.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit or follow us on .
Contact Information
Investor Contact:
Media Contact:
FAQ
When is ATAI presenting at the Jefferies Global Healthcare Conference 2025?
What type of company is ATAI Life Sciences?
Where can investors watch ATAI's conference presentations?
When is ATAI's presentation at the H.C. Wainwright Neuro Conference 2025?
